VIRGINIA RETIREMENT SYSTEMS ET Al Takes $348,000 Position in Option Care Health, Inc. $OPCH

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 10,700 shares of the company's stock, valued at approximately $348,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. USA Financial Formulas bought a new stake in shares of Option Care Health in the 2nd quarter valued at about $26,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of Option Care Health by 1,492.9% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock valued at $31,000 after acquiring an additional 836 shares during the last quarter. Brooklyn Investment Group increased its stake in shares of Option Care Health by 186.6% in the 1st quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock valued at $42,000 after acquiring an additional 780 shares during the last quarter. Bessemer Group Inc. increased its stake in Option Care Health by 62.3% during the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after purchasing an additional 599 shares in the last quarter. Finally, Wealthquest Corp bought a new stake in Option Care Health during the 1st quarter worth approximately $66,000. 98.05% of the stock is owned by institutional investors.

Option Care Health Price Performance

Shares of OPCH opened at $27.91 on Friday. The stock has a market capitalization of $4.53 billion, a P/E ratio of 22.33, a P/E/G ratio of 1.69 and a beta of 0.88. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $35.53. The company has a 50 day moving average of $27.99 and a 200-day moving average of $30.09. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.01. The company had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.35 billion. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The business's quarterly revenue was up 15.4% on a year-over-year basis. During the same period last year, the business earned $0.30 EPS. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts forecast that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were purchased at an average cost of $27.15 per share, with a total value of $977,400.00. Following the completion of the transaction, the director owned 375,390 shares of the company's stock, valued at $10,191,838.50. The trade was a 10.61% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Norman L. Wright purchased 3,411 shares of the company's stock in a transaction on Tuesday, September 9th. The shares were purchased at an average cost of $29.31 per share, for a total transaction of $99,976.41. Following the completion of the transaction, the director directly owned 15,501 shares of the company's stock, valued at approximately $454,334.31. This represents a 28.21% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 59,411 shares of company stock worth $1,627,576. Insiders own 0.64% of the company's stock.

Analysts Set New Price Targets

OPCH has been the subject of a number of research reports. Citigroup reissued an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Barrington Research reissued an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a research note on Tuesday, September 23rd. TD Cowen initiated coverage on Option Care Health in a research note on Thursday, October 2nd. They set a "hold" rating and a $30.00 target price for the company. Weiss Ratings reissued a "hold (c)" rating on shares of Option Care Health in a research note on Saturday. Finally, JMP Securities increased their target price on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research note on Thursday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.10.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

Want to see what other hedge funds are holding OPCH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Option Care Health, Inc. (NASDAQ:OPCH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.